The purpose of this study is to evaluate drug-drug interaction by comparing the pharmacokinetics (PK)/pharmacodynamics (PD), safety, and tolerability of single/multiple doses of DWP16001 , DWC202001 and DWC202002 alone or in combination in healthy male adults.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
34
Tablets, Oral, once daily single dose
Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Seoul National University Hospital
Seoul, South Korea
Cmax of DWP16001
Peak Plasma Concetration
Time frame: 0-72 hours
AUClast of DWP16001
Area under the plasma concentration versus time curve
Time frame: 0-72 hours
Cmax,ss of DWC202001 and DWC202002
Peak Plasma Concetration at steady-state
Time frame: 0-72 hours
AUCτ,ss of DWC202001 and DWC202002
Area under the plasma concentration versus time curve at Tau, steady-state
Time frame: 0-72 hours
Tmax of DWP 16001, DWC202001 and DWC202002
Time at Cmax
Time frame: 0-72 hours
T1/2 of DWP 16001, DWC202001 and DWC202002
Time frame: 0-72 hours
CL/F of DWC202001 and DWC202002
Time frame: 0-72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.